The low doses of Pfizer BioNTech’s COVID-19 vaccine were safe and effective for children ages 5 and 11, the two companies announced today.
Pfizer and BioNTech will submit the data to regulatory agencies in the United States and around the world for approval as soon as possible. Announced in a statement..
Their findings, which have not yet been peer-reviewed, come from clinical trials in 2,268 children aged 5 to 11 years. Young participants were given lower doses (10 μg, 21 day intervals) than given. Persons 12 years and older (30 µg, every 21 days).
One month after the second dose, participants showed antibody responses comparable to those aged 16-25 years who received 30 µg in a previous study. According to the statement, the vaccine was safe and well tolerated, with side effects similar to those observed in the elderly group.
“In the last nine months, hundreds of millions of people over the age of 12 have been with us from around the world. COVID-19 vaccineAlbert Bourla, Chairman and Chief Executive Officer of Pfizer, said in a statement. The serious threat it poses to children. “
Since July, he added, the number of pediatric COVID-19 cases has skyrocketed by 240% in the United States.
Children over the age of 12 are allowed to receive the Pfizer-BioNTech vaccine in the United States. The other two vaccines given in the United States (manufactured by Moderna, Johnson, and Johnson) have not yet been approved for children under the age of 18. Live science previously reported..
In a statement, the two companies said data on the safety and efficacy of the Pfizer-BioNTech vaccine in people under the age of 5 in the same clinical trial could be released later this year.
In this study, children under the age of 5 will be given a lower 3 µg vaccine.
Originally published in Live Science.
Pfizer says the COVID-19 vaccine is safe and effective for young children
Source link Pfizer says the COVID-19 vaccine is safe and effective for young children